Myelofibrosis 2012: It's complicated

Therapeutic Advances in Hematology

Volumn 3, Issue 3, 2012, Pages 131-146

  Hubbeling, Harper G ^a   Frank, Dale M ^a   Hexner, Elizabeth O ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

essential thrombocytosis; hematopoietic stem cell transplantation; interferon; JAK2 V617F; myelofibrosis; myeloproliferative neoplasms; polycythemia vera; TET2

Indexed keywords

ADAPTOR PROTEIN; ANTITHROMBOCYTIC AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; JANUS KINASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LNK PROTEIN; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA INTERFERON; STAT PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIANGIOGENIC ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA DAMAGE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ESSENTIAL THROMBOCYTOSIS; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOCYTE COUNT; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MISSENSE MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR SUPPRESSOR GENE;

EID: 84993730779     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712437754     Document Type: Article

References (83)

1. Abdel-Wahab O. Mullally A. Hedvat C. Garcia-Manero G. Patel J. Wadleigh M. et al. (2009) Genetic characterization of TET1, TET2, and TET 3 alterations in myeloid malignancies. Blood 114: 144–147.
2. Alchalby H. Badbaran A. Zabelina T. Kobbe G. Hahn J. Wolff D. et al. (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116: 3572–3581.
3. Ballen K.K. Shrestha S. Sobocinski K.A. Zhang M.J. Bashey A. Bolwell B.J. et al. (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16: 358–367.
4. Barbui T. Barosi G. Birgegard G. Cervantes F. Finazzi G. Griesshammer M. et al. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29: 761–770.
5. Barbui T. Carobbio A. Cervantes F. Vannucchi A.M. Guglielmelli P. Antonioli E. et al. (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115: 778–782.
6. Baxter E.J. Scott L.M. Campbell P.J. East C. Fourouclas N. Swanton S. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061.
7. Beer P.A. Delhommeau F. Le Couedic J.P. Dawson M.A. Chen E. Bareford D. et al. (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115: 2891–2900.
8. Bejar R. Stevenson K. Abdel-Wahab O. Galili N. Nilsson B. Garcia-Manero G. et al. (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496–2506.
9. Campbell P.J. (2009) Somatic and germline genetics at the JAK2 locus. Nat Genet 41: 385–386.
10. Campbell P.J. Green A.R. (2006) The myeloproliferative disorders. N Engl J Med 355: 2452–2466.
11. Cervantes F. Pereira A. Esteve J. Rafel M. Cobo F. Rozman C. et al. (1997) Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 97: 635–640.
12. Cervantes F. Dupriez B. Pereira A. Passamonti F. Reilly J.T. Morra E. et al. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 (13): 2895–2901.
13. Ciurea S.O. de Lima M. Giralt S. Saliba R. Bueso-Ramos C. Andersson B.S. et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16: 555–559.
14. Dameshek W. (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375.
15. Dawson M.A. Bannister A.J. Gottgens B. Foster S.D. Bartke T. Green A.R. et al. (2009) JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819–822.
16. Delhommeau F. Dupont S. Della Valle V. James C. Trannoy S. Masse A. et al. (2009) Mutation in TET 2 in myeloid cancers. N Engl J Med 360: 2289–2301.
17. Dolgin E. (2011) Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov 10: 717–718.
18. Druker B.J. Guilhot F. O'Brien S.G. Gathmann I. Kantarjian H. Gattermann N. et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417.
19. Dupriez B. Morel P. Demory J.L. Lai J.L. Simon M. Plantier I. et al. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88: 1013–1018.
20. Essers M.A. Offner S. Blanco-Bose W.E. Waibler Z. Kalinke U. Duchosal M.A. et al. (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458: 904–908.
21. Gangat N. Caramazza D. Vaidya R. George G. Begna K. Schwager S. et al. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29: 392–397.
22. Ghaffari S. Kitidis C. Fleming M.D. Neubauer H. Pfeffer K. Lodish H.F. (2001) Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors. Blood 98: 2948–2957.
23. Guardiola P. Anderson J.E. Bandini G. Cervantes F. Runde V. Arcese W. et al. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93: 2831–2838.
24. Guglielmelli P. Barosi G. Rambaldi A. Marchioli R. Masciulli A. Tozzi L. et al. (2011 a) Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1 / 2 study in patients with myelofibrosis. Blood 118: 2069–2076.
25. Guglielmelli P. Barosi G. Specchia G. Rambaldi A. Lo Coco F. Antonioli E. et al. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114: 1477–1483.
26. Guglielmelli P. Biamonte F. Score J. Hidalgo-Curtis C. Cervantes F. Maffioli M. et al. (2011 b) EZH 2 mutational status predicts poor survival in myelofibrosis. Blood, in press.
27. Gupta V. Kroger N. Aschan J. Xu W. Leber B. Dalley C. et al. (2009) A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 44: 317–320.
28. Hexner E.O. Serdikoff C. Jan M. Swider C.R. Robinson C. Yang S. et al. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663–5671.
29. Ianotto J.C. Kiladjian J.J. Demory J.L. Roy L. Boyer F. Rey J. et al. (2009) PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 146: 223–225.
30. James C. Ugo V. Le Couedic J.P. Staerk J. Delhommeau F. Lacout C. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148.
31. Jones A.V. Campbell P.J. Beer P.A. Schnittger S. Vannucchi A.M. Zoi K. et al. (2010) The JAK2 46 / 1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115: 4517–4523.
32. Jones A.V. Chase A. Silver R.T. Oscier D. Zoi K. Wang Y.L. et al. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41: 446–449.
33. Kerbauy D.M. Gooley T.A. Sale G.E. Flowers M.E. Doney K.C. Georges G.E. et al. (2007). Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13: 355–365.
34. Kiladjian J.J. Cassinat B. Chevret S. Turlure P. Cambier N. Roussel M. et al. (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112: 3065–3072.
35. Kiladjian J.J. Masse A. Cassinat B. Mokrani H. Teyssandier I. Le Couedic J.P. et al. (2010) Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET 2 mutant cells. Leukemia 24: 1519–1523.
36. Kiladjian J.J. Mesa R.A. Hoffman R. (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117: 4706–4715.
37. Kilpivaara O. Mukherjee S. Schram A.M. Wadleigh M. Mullally A. Ebert B.L. et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41: 455–459.
38. Klampfl T. Harutyunyan A. Berg T. Gisslinger B. Schalling M. Bagienski K. et al. (2011) Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118: 167–176.
39. Koppikar P. Abdel-Wahab O. Hedvat C. Marubayashi S. Patel J. Goel A. et al. (2010) Efficacy of the JAK2 inhibitor INCB 16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115: 2919–2927.
40. Kralovics R. Passamonti F. Buser A.S. Teo S.S. Tiedt R. Passweg J.R. et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790.
41. Kroger N. Alchalby H. Klyuchnikov E. Badbaran A. Hildebrandt Y. Ayuk F. et al. (2009 a) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113: 1866–1868.
42. Kroger N. Holler E. Kobbe G. Bornhauser M. Schwerdtfeger R. Baurmann H. et al. (2009 b) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114: 5264–5270.
43. Levine R.L. Wadleigh M. Cools J. Ebert B.L. Wernig G. Huntly B.J. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397.
44. Li J. Spensberger D. Ahn J.S. Anand S. Beer P.A. Ghevaert C. et al. (2010) JAK2V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2V617F-positive essential thrombocythemia. Blood 116: 1528–1538.
45. Lissandre S. Bay J.O. Cahn J.Y. Porcher R. Cacheux V. Cabrespine A. et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 46: 557–561.
46. Liu F. Zhao X. Perna F. Wang L. Koppikar P. Abdel-Wahab O. et al. (2011) JAK2V617F-mediated phosphorylation of PRMT 5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19: 283–294.
47. Marubayashi S. Koppikar P. Taldone T. Abdel-Wahab O. West N. Bhagwat N. et al. (2010) HSP 90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120: 3578–3593.
48. Moran-Crusio K. Reavie L. Shih A. Abdel-Wahab O. Ndiaye-Lobry D. Lobry C. et al. (2011) Tet 2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20: 11–24.
49. Nowell P.C. Hungerford D.A. (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85–109.
50. Oh S.T. (2011) When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms. Ther Adv Hematol 2: 11–19.
51. Oh S.T. Simonds E.F. Jones C. Hale M.B. Goltsev Y. Gibbs K.D. Jr et al. (2010) Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116: 988–992.
52. Olcaydu D. Harutyunyan A. Jager R. Berg T. Gisslinger B. Pabinger I. et al. (2009 a) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450–454.
53. Olcaydu D. Skoda R.C. Looser R. Li S. Cazzola M. Pietra D. et al. (2009 b) The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23: 1924–1926.
54. Pardanani A. Gotlib J.R. Jamieson C. Cortes J.E. Talpaz M. Stone R.M. et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789–796.
55. Passamonti F. Cervantes F. Vannucchi A.M. Morra E. Rumi E. Pereira A. et al. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115: 1703–1708.
56. Patriarca F. Bacigalupo A. Sperotto A. Isola M. Soldano F. Bruno B. et al. (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93: 1514-1522.
57. Perna F. Gurvich N. Hoya-Arias R. Abdel-Wahab O. Levine R.L. Asai T. et al. (2010) Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood 116: 2812–2821.
58. Pikman Y. Lee B.H. Mercher T. McDowell E. Ebert B.L. Gozo M. et al. (2006) MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med 3 (7): e270.
59. Quivoron C. Couronne L. Della Valle V. Lopez C.K. Plo I. Wagner-Ballon O. et al. (2011) TET 2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20: 25–38.
60. Rambaldi A. Dellacasa C.M. Finazzi G. Carobbio A. Ferrari M.L. Guglielmelli P. et al. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150: 446–455.
61. Robin M. Tabrizi R. Mohty M. Furst S. Michallet M. Bay J.O. et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Br J Haematol 152: 331–339.
62. Samuelson S. Sandmaier B.M. Heslop H.E. Popat U. Carrum G. Champlin R.E. et al. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol 153: 76–82.
63. Sato T. Onai N. Yoshihara H. Arai F. Suda T. Ohteki T. (2009) Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 15: 696–700.
64. Schnittger S. Bacher U. Kern W. Haferlach C. Haferlach T. (2007) JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML. Leukemia 21: 183–184.
65. Scott L.M. Scott M.A. Campbell P.J. Green A.R. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108: 2435–2437.
66. Scott L.M. Tong W. Levine R.L. Scott M.A. Beer P.A. Stratton M.R. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356: 459–468.
67. Seaman V. Jumaan A. Yanni E. Lewis B. Neyer J. Roda P. et al. (2009) Use of molecular testing to identify a cluster of patients with polycythemia vera in eastern Pennsylvania. Cancer Epidemiol Biomarkers Prev 18: 534–540.
68. Silver R.T. Vandris K. Goldman J.J. (2011) Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117: 6669–6672.
69. Snyder D.S. Palmer J. Gaal K. Stein A.S. Pullarkat V. Sahebi F. et al. (2010) Improved outcomes using tacrolimus / sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biol Blood Marrow Transplant 16: 281–286.
70. Sorror M.L. Maris M.B. Storb R. Baron F. Sandmaier B.M. Maloney D.G. et al. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106: 2912–2919.
71. Spivak J.L. Silver R.T. (2008) The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112: 231–239.
72. Stein B.L. Williams D.M. O'Keefe C. Rogers O. Ingersoll R.G. Spivak J.L. et al. (2011) Disruption of the ASXL 1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 96: 1462–1469.
73. Swerdlow S.H., for the International Agency for Research on Cancer, World Health Organization and Louis A. Duhring Fund (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer, p. 439, available at: http://hdl.library.upenn.edu/1017.12/366308.
74. Tefferi A. Lasho T.L. Huang J. Finke C. Mesa R.A. Li C.Y. et al. (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22: 756–761.
75. Thepot S. Itzykson R. Seegers V. Raffoux E. Quesnel B. Chait Y. et al. (2010) Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116: 3735–3742.
76. Thiele J. Kvasnicka H.M. Mullauer L. Buxhofer-Ausch V. Gisslinger B. Gisslinger H. (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117: 5710–5718.
77. Tong W. Zhang J. Lodish H.F. (2005) Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105: 4604–4612.
78. Vannucchi A.M. Pieri L. Guglielmelli P. (2011) JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol 2: 21–32.
79. Velazquez L. Cheng A.M. Fleming H.E. Furlonger C. Vesely S. Bernstein A. et al. (2002) Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 195: 1599–1611.
80. Verstovsek S. Kantarjian H. Mesa R.A. Pardanani A.D. Cortes-Franco J. Thomas D.A. et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117–1127.
81. Weinstein J.N. Myers T.G. O'Connor P.M. Friend S.H. Fornace A.J. Jr Kohn K.W. et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343–349.
82. Wernig G. Mercher T. Okabe R. Levine R.L. Lee B.H. Gilliland D.G. (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107: 4274–4281.
83. Xiong Z. Yan Y. Liu E. Silver R.T. Verstovsek S. Yang F. et al. (2007) Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clin Immunol 122: 279–287.